Key result
Apixaban outperforms warfarin for stroke prevention in AFib patients across all elderly age groups.
Why the study?
Does apixaban improve stroke prevention compared to warfarin in patients with atrial fibrillation across different age groups?
Does apixaban improve stroke prevention compared to warfarin in patients with atrial fibrillation across different age groups?
Apixaban provides consistent relative benefits over warfarin for stroke prevention in AF across all age groups, with greater absolute benefits in older patients.
Answers are grounded in this paper and cite their sources.
Supports preferential apixaban use over warfarin in elderly AF for greater absolute stroke prevention; confirms consistency of benefits across ages in RCT data.
The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.
No takes yet. Share an insight, caveat, or question.
Halvorsen et al. (2014) studied this question. Apixaban provided greater absolute benefits for stroke prevention in elderly patients with atrial fibrillation compared to warfarin, consistent across all age groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: